and Rudolf Jaenisch compares and contrasts the properties of pluripotent embryonic stem cells with those of laboratory-generated pluripotent cells.
The Poster (www.nature.com/nrm/posters/stemcellreprogramming) was produced with generous support from STEMCELL Technologies. Realistically, however, iPS-cell technology remains far removed from the clinic. For now, it will most likely be used to produce models for studying disease and testing drugs. Indeed, the first disease-specific iPS cells were recently reported, just 2 years after iPS-cell technology was developed. 
